Literature DB >> 9393736

Patterns of chromosomal alterations in metastasizing and nonmetastasizing primary head and neck carcinomas.

U Bockmühl1, S Petersen, S Schmidt, G Wolf, V Jahnke, M Dietel, I Petersen.   

Abstract

In an attempt to define chromosomal alterations that are associated with the metastatic phenotype, we investigated a total of 29 metastasizing (pN+) and 19 non-metastasizing (pN0) head and neck squamous cell carcinomas by comparative genomic hybridization (CGH). The analysis indicated that the pN0 tumors carried preferentially overrepresentations of chromosomes 5p, 6p, and 7p and that the pN+ tumors were frequently characterized by deletions on chromosomes 7q, 10q, 11p, 11q, 15q, and 20p and overrepresentations of the chromosomes 19q and 20q. In particular, the use of difference histograms and statistical analysis indicated that the deletions on chromosomes 10q25-q26 and 11p13-p14 were highly significant for metastasizing carcinomas. The findings on chromosome 10q were supported by loss of heterozygosity analysis in the primary tumors and eight synchronous lymph node metastases using four microsatellite polymorphisms. The data suggest that distinct patterns of genetic lesions are responsible for the metastatic phenotype of head and neck squamous cell carcinomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9393736

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Evidence for a prostate cancer-susceptibility locus on chromosome 20.

Authors:  R Berry; J J Schroeder; A J French; S K McDonnell; B J Peterson; J M Cunningham; S N Thibodeau; D J Schaid
Journal:  Am J Hum Genet       Date:  2000-05-16       Impact factor: 11.025

2.  Genetic imbalances with impact on survival in head and neck cancer patients.

Authors:  U Bockmühl; K Schlüns; I Küchler; S Petersen; I Petersen
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

3.  Influential factors on tumor recurrence in head and neck cancer patients.

Authors:  Christoph Matthias; Ulrich Harréus; Richard Strange
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-07-08       Impact factor: 2.503

4.  Recurrent chromosomal imbalances detected in biopsy material from oral premalignant and malignant lesions by combined tissue microdissection, universal DNA amplification, and comparative genomic hybridization.

Authors:  R G Weber; M Scheer; I A Born; S Joos; J M Cobbers; C Hofele; G Reifenberger; J E Zöller; P Lichter
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

5.  Tissue microarray analysis of EGFR and HER2 oncogene copy number alterations in squamous cell carcinoma of the larynx.

Authors:  Denitsa Krasimirova Koynova; Vesselina Sainova Tsenova; Renata Stoiancho Jankova; Plamen Borisov Gurov; Draga Ivanova Toncheva
Journal:  J Cancer Res Clin Oncol       Date:  2004-12-08       Impact factor: 4.553

6.  Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization.

Authors:  K Bleuel; S Popp; N E Fusenig; E J Stanbridge; P Boukamp
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

Review 7.  The molecular biology of head and neck cancer.

Authors:  C René Leemans; Boudewijn J M Braakhuis; Ruud H Brakenhoff
Journal:  Nat Rev Cancer       Date:  2010-12-16       Impact factor: 60.716

Review 8.  Anoikis mediators in oral squamous cell carcinoma.

Authors:  J Bunek; P Kamarajan; Y L Kapila
Journal:  Oral Dis       Date:  2010-11-29       Impact factor: 3.511

Review 9.  Chromosomal aberrations related to metastasis of human solid tumors.

Authors:  Lun-Xiu Qin
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

10.  Endoreduplication in conjunction with tumor progression in an aneuploid laryngeal squamous cell carcinoma.

Authors:  Michael J Schwerer; Jörg Hemmer; Klaus Kraft; Heinz Maier; Peter Möller; Thomas F E Barth
Journal:  Virchows Arch       Date:  2003-05-15       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.